采用锁核酸探针的新型实时聚合酶链反应检测法评估法国氟喹诺酮敏感肺炎链球菌分离株中ParC突变的流行情况。
New real-time PCR assay using locked nucleic acid probes to assess prevalence of ParC mutations in fluoroquinolone-susceptible Streptococcus pneumoniae isolates from France.
作者信息
Decousser Jean-Winoc, Methlouthi Imen, Pina Patrick, Collignon Anne, Allouch Pierre
机构信息
Laboratoire de Biologie, Centre Hospitalier de Dourdan, 2 Rue du Potelet, 91415 Dourdan, France.
出版信息
Antimicrob Agents Chemother. 2006 Apr;50(4):1594-8. doi: 10.1128/AAC.50.4.1594-1598.2006.
Abstract
A real-time PCR assay with locked nucleic acid probes was developed to screen mutations at codons 79 and 83 of the Streptococcus pneumoniae parC gene. Only silent mutations were detected among 236 French invasive fluoroquinolone-susceptible strains. This test could be useful for some high-risk patients or in national surveys.
摘要
开发了一种使用锁核酸探针的实时聚合酶链反应检测方法，以筛查肺炎链球菌parC基因第79和83密码子处的突变。在236株法国侵袭性氟喹诺酮敏感菌株中仅检测到沉默突变。该检测方法可能对一些高危患者或全国性调查有用。
相似文献
1
New real-time PCR assay using locked nucleic acid probes to assess prevalence of ParC mutations in fluoroquinolone-susceptible Streptococcus pneumoniae isolates from France.
Antimicrob Agents Chemother. 2006 Apr;50(4):1594-8. doi: 10.1128/AAC.50.4.1594-1598.2006.
2
Detection of parC mutations in Streptococcus pneumoniae by Real-time PCR and Taqman-MGB probes.
J Microbiol Methods. 2007 Apr;69(1):214-7. doi: 10.1016/j.mimet.2006.12.016. Epub 2006 Dec 30.
3
An extended PCR-RFLP assay for detection of parC, parE and gyrA mutations in fluoroquinolone-resistant Streptococcus pneumoniae.
J Antimicrob Chemother. 2004 Apr;53(4):682-3. doi: 10.1093/jac/dkh147. Epub 2004 Mar 10.
4
Are fluoroquinolone-susceptible isolates of Streptococcus pneumoniae really susceptible? A comparison of resistance mechanisms in Canadian isolates from 1997 and 2003.
J Antimicrob Chemother. 2005 Oct;56(4):769-72. doi: 10.1093/jac/dki315. Epub 2005 Aug 26.
5
Call for the international adoption of microbiological breakpoints for fluoroquinolones and Streptococcus pneumoniae.
Int J Antimicrob Agents. 2006 Sep;28(3):266-9. doi: 10.1016/j.ijantimicag.2006.04.007. Epub 2006 Aug 9.
6
Effect of low-level resistance on subsequent enrichment of fluoroquinolone-resistant Streptococcus pneumoniae in rabbits.
J Infect Dis. 2004 Oct 15;190(8):1472-5. doi: 10.1086/423853. Epub 2004 Sep 8.
7
In vitro activity of sitafloxacin against clinical strains of Streptococcus pneumoniae with defined amino acid substitutions in QRDRs of gyrase A and topoisomerase IV.
J Antimicrob Chemother. 2006 Dec;58(6):1279-82. doi: 10.1093/jac/dkl427. Epub 2006 Oct 20.
8
Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae.
J Antimicrob Chemother. 2006 Sep;58(3):601-9. doi: 10.1093/jac/dkl292. Epub 2006 Jul 19.
9
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
Antimicrob Agents Chemother. 2008 Nov;52(11):4155-8. doi: 10.1128/AAC.00082-08. Epub 2008 Aug 25.
10
In vitro selection of resistance in Streptococcus pneumoniae at in vivo fluoroquinolone concentrations.
J Antimicrob Chemother. 2009 Apr;63(4):721-7. doi: 10.1093/jac/dkp020. Epub 2009 Feb 13.
引用本文的文献
1
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
Antimicrob Agents Chemother. 2008 Nov;52(11):4155-8. doi: 10.1128/AAC.00082-08. Epub 2008 Aug 25.
本文引用的文献
1
A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance.
Clin Infect Dis. 2005 Jul 1;41(1):118-21. doi: 10.1086/430829. Epub 2005 May 26.
2
Fluoroquinolone prescribing in the United States: 1995 to 2002.
Am J Med. 2005 Mar;118(3):259-68. doi: 10.1016/j.amjmed.2004.09.015.
3
Outpatient antibiotic use in Europe and association with resistance: a cross-national database study.
Lancet. 2005;365(9459):579-87. doi: 10.1016/S0140-6736(05)17907-0.
4
The molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations.
Clin Infect Dis. 2005 Jan 15;40(2):225-35. doi: 10.1086/426817. Epub 2004 Dec 21.
5
Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States.
Diagn Microbiol Infect Dis. 2005 Jan;51(1):31-7. doi: 10.1016/j.diagmicrobio.2004.08.017.
6
Fluoroquinolone resistance in penicillin-resistant Streptococcus pneumoniae clones, Spain.
Emerg Infect Dis. 2004 Oct;10(10):1751-9. doi: 10.3201/eid1010.040382.
7
Invasive Streptococcus pneumoniae in France: antimicrobial resistance, serotype, and molecular epidemiology findings from a monthly national study in 2000 to 2002.
Antimicrob Agents Chemother. 2004 Sep;48(9):3636-9. doi: 10.1128/AAC.48.9.3636-3639.2004.
8
Designing fluoroquinolone breakpoints for Streptococcus pneumoniae by using genetics instead of pharmacokinetics-pharmacodynamics.
Antimicrob Agents Chemother. 2004 Sep;48(9):3630-5. doi: 10.1128/AAC.48.9.3630-3635.2004.
9
An extended PCR-RFLP assay for detection of parC, parE and gyrA mutations in fluoroquinolone-resistant Streptococcus pneumoniae.
J Antimicrob Chemother. 2004 Apr;53(4):682-3. doi: 10.1093/jac/dkh147. Epub 2004 Mar 10.
10
Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults.
Clin Infect Dis. 2003 Dec 1;37(11):1405-33. doi: 10.1086/380488. Epub 2003 Nov 3.
Zotero 插件